Parkside Financial Bank & Trust Reduces Stock Holdings in Boston Scientific Co. (NYSE:BSX)

Parkside Financial Bank & Trust decreased its stake in Boston Scientific Co. (NYSE:BSXFree Report) by 6.6% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 3,253 shares of the medical equipment provider’s stock after selling 229 shares during the quarter. Parkside Financial Bank & Trust’s holdings in Boston Scientific were worth $188,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. PDS Planning Inc lifted its stake in shares of Boston Scientific by 11.1% during the 4th quarter. PDS Planning Inc now owns 4,964 shares of the medical equipment provider’s stock worth $287,000 after acquiring an additional 496 shares during the last quarter. Aspire Private Capital LLC lifted its stake in shares of Boston Scientific by 10.9% during the 4th quarter. Aspire Private Capital LLC now owns 7,885 shares of the medical equipment provider’s stock worth $456,000 after acquiring an additional 773 shares during the last quarter. California Public Employees Retirement System lifted its stake in shares of Boston Scientific by 3.0% during the 4th quarter. California Public Employees Retirement System now owns 3,798,511 shares of the medical equipment provider’s stock worth $219,592,000 after acquiring an additional 112,222 shares during the last quarter. Jennison Associates LLC lifted its stake in shares of Boston Scientific by 1.3% during the 4th quarter. Jennison Associates LLC now owns 1,227,833 shares of the medical equipment provider’s stock worth $70,981,000 after acquiring an additional 15,596 shares during the last quarter. Finally, Commerzbank Aktiengesellschaft FI bought a new stake in shares of Boston Scientific during the 4th quarter worth approximately $366,000. 89.07% of the stock is owned by institutional investors.

Boston Scientific Stock Up 5.7 %

Shares of BSX stock opened at $72.91 on Thursday. Boston Scientific Co. has a 1-year low of $48.35 and a 1-year high of $74.39. The stock’s fifty day moving average price is $67.53 and its 200 day moving average price is $60.28. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.32 and a quick ratio of 0.82. The company has a market cap of $106.97 billion, a price-to-earnings ratio of 68.14, a price-to-earnings-growth ratio of 2.42 and a beta of 0.78.

Boston Scientific (NYSE:BSXGet Free Report) last announced its earnings results on Wednesday, January 31st. The medical equipment provider reported $0.55 earnings per share for the quarter, topping the consensus estimate of $0.51 by $0.04. Boston Scientific had a return on equity of 15.99% and a net margin of 11.19%. The firm had revenue of $3.73 billion for the quarter, compared to the consensus estimate of $3.59 billion. During the same period in the previous year, the business earned $0.45 EPS. On average, research analysts expect that Boston Scientific Co. will post 2.25 earnings per share for the current fiscal year.

Analyst Ratings Changes

BSX has been the subject of a number of research analyst reports. Mizuho raised Boston Scientific from a “neutral” rating to a “buy” rating and lifted their target price for the company from $65.00 to $80.00 in a research report on Thursday, February 1st. Raymond James lifted their target price on Boston Scientific from $67.00 to $73.00 and gave the company a “strong-buy” rating in a research report on Thursday, February 1st. Royal Bank of Canada lifted their target price on Boston Scientific from $70.00 to $78.00 and gave the company an “outperform” rating in a research report on Monday, April 15th. Evercore ISI lifted their target price on Boston Scientific from $68.00 to $72.00 and gave the company an “outperform” rating in a research report on Thursday, April 4th. Finally, Citigroup lifted their target price on Boston Scientific from $71.00 to $79.00 and gave the company a “buy” rating in a research report on Wednesday, April 3rd. Two equities research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $69.95.

Get Our Latest Report on Boston Scientific

Insider Buying and Selling

In other Boston Scientific news, Director Edward J. Ludwig sold 7,000 shares of the business’s stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $65.03, for a total transaction of $455,210.00. Following the sale, the director now owns 41,374 shares in the company, valued at approximately $2,690,551.22. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Boston Scientific news, CFO Daniel J. Brennan sold 13,662 shares of the business’s stock in a transaction dated Tuesday, February 20th. The stock was sold at an average price of $65.86, for a total transaction of $899,779.32. Following the sale, the chief financial officer now owns 271,542 shares in the company, valued at approximately $17,883,756.12. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Edward J. Ludwig sold 7,000 shares of the business’s stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $65.03, for a total value of $455,210.00. Following the sale, the director now owns 41,374 shares in the company, valued at approximately $2,690,551.22. The disclosure for this sale can be found here. Insiders have sold a total of 50,979 shares of company stock worth $3,418,529 in the last ninety days. 0.50% of the stock is owned by insiders.

About Boston Scientific

(Free Report)

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

Featured Articles

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSXFree Report).

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.